| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2026 ( Subtotal = $697,200 ) |
| | 2026 | 2026 | ABVACC, INC. | 4 RESEARCH CT | ROCKVILLE | MD | 20850-3220 | MONTGOMERY | USA | R01AI111205 | Multivalent Toxoid Vaccine for recurrent Staphylococccus aureus disease | 000 | 10 | NIH | 2/19/2026 | $697,200 |
| | 2026 | 2025 | ABVACC, INC. | 4 RESEARCH CT | ROCKVILLE | MD | 20850-3220 | MONTGOMERY | USA | R43AI181292 | Development of a Marburgvirus subunit vaccineadjuvanted with a novel TLR7/TLR8 agonist | 000 | 2 | NIH | 11/13/2025 | $0 |
| | 2026 | 2025 | ABVACC, INC. | 4 RESEARCH CT | ROCKVILLE | MD | 20850-3220 | MONTGOMERY | USA | R44AI177045 | Prophylactic Immunotherapy for Marburg Virus Disease Outbreak Control | 000 | 3 | NIH | 2/3/2026 | $0 |
|
| Issue Date FY: 2025 ( Subtotal = $3,495,488 ) |
| | 2025 | 2025 | ABVACC, INC. | 4 RESEARCH CT | ROCKVILLE | MD | 20850-3220 | MONTGOMERY | USA | R01AI111205 | Multivalent Toxoid Vaccine for recurrent Staphylococccus aureus disease | 000 | 9 | NIH | 2/13/2025 | $646,138 |
| | 2025 | 2025 | ABVACC, INC. | 4 RESEARCH CT | ROCKVILLE | MD | 20850-3220 | MONTGOMERY | USA | R43AI181292 | Development of a Marburgvirus subunit vaccineadjuvanted with a novel TLR7/TLR8 agonist | 000 | 2 | NIH | 1/17/2025 | $297,099 |
| | 2025 | 2025 | ABVACC, INC. | 4 RESEARCH CT | ROCKVILLE | MD | 20850-3220 | MONTGOMERY | USA | R01AI193221 | A multimodal approach for immunotherapy of Staphylococcus aureus bacteremia | 000 | 1 | NIH | 8/22/2025 | $638,953 |
| | 2025 | 2025 | ABVACC, INC. | 4 RESEARCH CT | ROCKVILLE | MD | 20850-3220 | MONTGOMERY | USA | R44AI177045 | Prophylactic Immunotherapy for Marburg Virus Disease Outbreak Control | 000 | 3 | NIH | 4/30/2025 | $914,818 |
| | 2025 | 2025 | ABVACC, INC. | 4 RESEARCH CT | ROCKVILLE | MD | 20850-3220 | MONTGOMERY | USA | R44AI179371 | Monoclonal Antibody Cocktail for Treatment of Marburg Virus Disease | 001 | 2 | NIH | 5/30/2025 | $1,000,000 |
| | 2025 | 2023 | ABVACC, INC. | 4 RESEARCH CT | ROCKVILLE | MD | 20850-3220 | MONTGOMERY | USA | R44AI155309 | Immunotherapy of MRSA Osteomyelitis | 000 | 3 | NIH | 9/9/2025 | -$376 |
| | 2025 | 2023 | ABVACC, INC. | 4 RESEARCH CT | ROCKVILLE | MD | 20850-3220 | MONTGOMERY | USA | R44AI179371 | Monoclonal Antibody Cocktail for Treatment of Marburg Virus Disease | 000 | 1 | NIH | 5/23/2025 | -$3 |
| | 2025 | 2022 | ABVACC, INC. | 4 RESEARCH CT | ROCKVILLE | MD | 20850-3220 | MONTGOMERY | USA | R44AI140932 | Development of a Universal Immunotherapeutic for Influenza Viruses | 000 | 4 | NIH | 2/24/2025 | $0 |
| | 2025 | 2021 | ABVACC, INC. | 4 RESEARCH CT | ROCKVILLE | MD | 20850-3220 | MONTGOMERY | USA | R01AI132204 | Rationally Designed Pan-Ebolavirus Vaccine | 000 | 6 | NIH | 4/23/2025 | -$171 |
| | 2025 | 2021 | ABVACC, INC. | 4 RESEARCH CT | ROCKVILLE | MD | 20850-3220 | MONTGOMERY | USA | R42AI122666 | Infection Site Targeted Antitoxin Antibody (ISTAb) against Bacillus anthracis | 000 | 6 | NIH | 2/19/2025 | -$970 |
|
| Issue Date FY: 2024 ( Subtotal = $3,026,414 ) |
| | 2024 | 2024 | ABVACC, INC. | 4 RESEARCH CT | ROCKVILLE | MD | 20850-3220 | MONTGOMERY | USA | R01AI146177 | Protective versus deleterious immune responses that impact vaccine efficacy against Staphylococcus aureus bloodstream infection | 003 | 5 | NIH | 3/28/2024 | $619,311 |
| | 2024 | 2024 | ABVACC, INC. | 4 RESEARCH CT | ROCKVILLE | MD | 20850-3220 | MONTGOMERY | USA | R43AI181292 | Development of a Marburgvirus subunit vaccineadjuvanted with a novel TLR7/TLR8 agonist | 000 | 1 | NIH | 2/26/2024 | $299,528 |
| | 2024 | 2024 | ABVACC, INC. | 4 RESEARCH CT | ROCKVILLE | MD | 20850-3220 | MONTGOMERY | USA | R01AI111205 | Multivalent Toxoid Vaccine for recurrent Staphylococccus aureus disease | 003 | 8 | NIH | 3/28/2024 | $649,379 |
| | 2024 | 2024 | ABVACC, INC. | 4 RESEARCH CT | ROCKVILLE | MD | 20850-3220 | MONTGOMERY | USA | R44AI177045 | Prophylactic Immunotherapy for Marburg Virus Disease Outbreak Control | 000 | 2 | NIH | 4/19/2024 | $918,483 |
| | 2024 | 2023 | ABVACC, INC. | 4 RESEARCH CT | ROCKVILLE | MD | 20850-3220 | MONTGOMERY | USA | R01AI111205 | Multivalent Toxoid Vaccine for recurrent Staphylococccus aureus disease | 001 | 7 | NIH | 2/14/2024 | $209,734 |
| | 2024 | 2023 | ABVACC, INC. | 4 RESEARCH CT | ROCKVILLE | MD | 20850-3220 | MONTGOMERY | USA | R01AI111205 | Multivalent Toxoid Vaccine for recurrent Staphylococccus aureus disease | 002 | 7 | NIH | 3/25/2024 | -$29,442 |
| | 2024 | 2023 | ABVACC, INC. | 4 RESEARCH CT | ROCKVILLE | MD | 20850-3220 | MONTGOMERY | USA | R44AI179371 | Monoclonal Antibody Cocktail for Treatment of Marburg Virus Disease | 000 | 1 | NIH | 6/5/2024 | $0 |
| | 2024 | 2023 | ABVACC, INC. | 4 RESEARCH CT | ROCKVILLE | MD | 20850-3220 | MONTGOMERY | USA | R01AI146177 | Protective versus deleterious immune responses that impact vaccine efficacy against Staphylococcus aureus bloodstream infection | 001 | 4 | NIH | 1/19/2024 | $13,387 |
| | 2024 | 2023 | ABVACC, INC. | 4 RESEARCH CT | ROCKVILLE | MD | 20850-3220 | MONTGOMERY | USA | R01AI146177 | Protective versus deleterious immune responses that impact vaccine efficacy against Staphylococcus aureus bloodstream infection | 002 | 4 | NIH | 3/26/2024 | -$62,983 |
| | 2024 | 2023 | ABVACC, INC. | 4 RESEARCH CT | ROCKVILLE | MD | 20850-3220 | MONTGOMERY | USA | R44AI155309 | Immunotherapy of MRSA Osteomyelitis | 001 | 3 | NIH | 1/19/2024 | $426,581 |
| | 2024 | 2022 | ABVACC, INC. | 4 RESEARCH CT | ROCKVILLE | MD | 20850-3220 | MONTGOMERY | USA | R44AI140932 | Development of a Universal Immunotherapeutic for Influenza Viruses | 001 | 4 | NIH | 1/19/2024 | $41,905 |
| | 2024 | 2022 | ABVACC, INC. | 4 RESEARCH CT | ROCKVILLE | MD | 20850-3220 | MONTGOMERY | USA | R44AI140932 | Development of a Universal Immunotherapeutic for Influenza Viruses | 002 | 4 | NIH | 2/27/2024 | $0 |
| | 2024 | 2021 | ABVACC, INC. | 4 RESEARCH CT | ROCKVILLE | MD | 20850-3220 | MONTGOMERY | USA | R01AI132204 | Rationally Designed Pan-Ebolavirus Vaccine | 002 | 6 | NIH | 3/12/2024 | -$133,721 |
| | 2024 | 2021 | ABVACC, INC. | 4 RESEARCH CT | ROCKVILLE | MD | 20850-3220 | MONTGOMERY | USA | R42AI122666 | Infection Site Targeted Antitoxin Antibody (ISTAb) against Bacillus anthracis | 001 | 6 | NIH | 1/19/2024 | $65,953 |
| | 2024 | 2021 | ABVACC, INC. | 4 RESEARCH CT | ROCKVILLE | MD | 20850-3220 | MONTGOMERY | USA | R01AI132204 | Rationally Designed Pan-Ebolavirus Vaccine | 001 | 6 | NIH | 1/19/2024 | $8,300 |
|
| Issue Date FY: 2023 ( Subtotal = $4,701,205 ) |
| | 2023 | 2023 | ABVACC, INC. | 4 RESEARCH CT | ROCKVILLE | MD | 20850-3220 | MONTGOMERY | USA | R44AI177045 | Prophylactic Immunotherapy for Marburg Virus Disease Outbreak Control | 000 | 1 | NIH | 5/12/2023 | $986,248 |
| | 2023 | 2023 | ABVACC, INC. | 4 RESEARCH CT | ROCKVILLE | MD | 20850-3220 | MONTGOMERY | USA | R01AI146177 | Protective versus deleterious immune responses that impact vaccine efficacy against Staphylococcus aureus bloodstream infection | 001 | 4 | NIH | 4/25/2023 | $726,553 |
| | 2023 | 2023 | ABVACC, INC. | 4 RESEARCH CT | ROCKVILLE | MD | 20850-3220 | MONTGOMERY | USA | R44AI155309 | Immunotherapy of MRSA Osteomyelitis | 001 | 3 | NIH | 4/21/2023 | $1,000,000 |
| | 2023 | 2023 | ABVACC, INC. | 4 RESEARCH CT | ROCKVILLE | MD | 20850-3220 | MONTGOMERY | USA | R44AI179371 | Monoclonal Antibody Cocktail for Treatment of Marburg Virus Disease | 000 | 1 | NIH | 8/11/2023 | $293,392 |
| | 2023 | 2023 | ABVACC, INC. | 4 RESEARCH CT | ROCKVILLE | MD | 20850-3220 | MONTGOMERY | USA | R01AI111205 | Multivalent Toxoid Vaccine for recurrent Staphylococccus aureus disease | 001 | 7 | NIH | 5/10/2023 | $700,012 |
| | 2023 | 2022 | ABVACC, INC. | 4 RESEARCH CT | ROCKVILLE | MD | 20850-3220 | MONTGOMERY | USA | R44AI140932 | Development of a Universal Immunotherapeutic for Influenza Viruses | 001 | 4 | NIH | 4/26/2023 | $380,000 |
| | 2023 | 2022 | ABVACC, INC. | 4 RESEARCH CT | ROCKVILLE | MD | 20850-3220 | MONTGOMERY | USA | R44AI140932 | Development of a Universal Immunotherapeutic for Influenza Viruses | 002 | 4 | NIH | 6/26/2023 | $0 |
| | 2023 | 2021 | ABVACC, INC. | 4 RESEARCH CT | ROCKVILLE | MD | 20850-3220 | MONTGOMERY | USA | R01AI132204 | Rationally Designed Pan-Ebolavirus Vaccine | 001 | 6 | NIH | 4/20/2023 | $300,000 |
| | 2023 | 2021 | ABVACC, INC. | 4 RESEARCH CT | ROCKVILLE | MD | 20850-3220 | MONTGOMERY | USA | R01AI132204 | Rationally Designed Pan-Ebolavirus Vaccine | 002 | 6 | NIH | 4/26/2023 | $0 |
| | 2023 | 2021 | ABVACC, INC. | 4 RESEARCH CT | ROCKVILLE | MD | 20850-3220 | MONTGOMERY | USA | R42AI122666 | Infection Site Targeted Antitoxin Antibody (ISTAb) against Bacillus anthracis | 001 | 6 | NIH | 5/26/2023 | $315,000 |
|
|
